DDD Partners LLC Has $270,000 Stock Holdings in Danaher Co. (NYSE:DHR)

DDD Partners LLC cut its position in Danaher Co. (NYSE:DHR) by 8.9% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 1,168 shares of the conglomerate’s stock after selling 114 shares during the quarter. DDD Partners LLC’s holdings in Danaher were worth $270,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Fairfield Bush & CO. lifted its position in shares of Danaher by 10.9% during the 1st quarter. Fairfield Bush & CO. now owns 4,840 shares of the conglomerate’s stock worth $1,420,000 after buying an additional 475 shares in the last quarter. Zions Bancorporation N.A. raised its holdings in shares of Danaher by 19.3% in the 1st quarter. Zions Bancorporation N.A. now owns 2,468 shares of the conglomerate’s stock worth $724,000 after purchasing an additional 400 shares during the period. Covestor Ltd raised its holdings in shares of Danaher by 76.8% in the 1st quarter. Covestor Ltd now owns 495 shares of the conglomerate’s stock worth $145,000 after purchasing an additional 215 shares during the period. NewEdge Advisors LLC raised its holdings in shares of Danaher by 14.1% in the 1st quarter. NewEdge Advisors LLC now owns 31,530 shares of the conglomerate’s stock worth $9,248,000 after purchasing an additional 3,897 shares during the period. Finally, Bridgewater Associates LP raised its holdings in shares of Danaher by 135.9% in the 1st quarter. Bridgewater Associates LP now owns 35,270 shares of the conglomerate’s stock worth $10,346,000 after purchasing an additional 20,320 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, SVP Daniel Raskas sold 23,757 shares of the stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the transaction, the senior vice president now directly owns 38,102 shares of the company’s stock, valued at $9,601,704. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Danaher news, SVP Daniel Raskas sold 23,757 shares of the company’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the sale, the senior vice president now owns 38,102 shares in the company, valued at $9,601,704. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Walter G. Lohr sold 3,289 shares of the stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $251.15, for a total transaction of $826,032.35. Following the sale, the director now owns 14,129 shares in the company, valued at approximately $3,548,498.35. The disclosure for this sale can be found here. Insiders sold a total of 32,957 shares of company stock valued at $8,265,802 over the last three months. Corporate insiders own 11.10% of the company’s stock.

Danaher Stock Performance

Shares of NYSE:DHR opened at $248.84 on Thursday. The company has a market cap of $184.07 billion, a price-to-earnings ratio of 38.94, a price-to-earnings-growth ratio of 3.77 and a beta of 0.84. The company has a 50-day moving average price of $246.68 and a 200-day moving average price of $230.40. The company has a current ratio of 1.68, a quick ratio of 1.37 and a debt-to-equity ratio of 0.31. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $259.00.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, January 30th. The conglomerate reported $2.09 EPS for the quarter, beating the consensus estimate of $1.91 by $0.18. The firm had revenue of $6.41 billion during the quarter, compared to the consensus estimate of $6.10 billion. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The company’s quarterly revenue was down 10.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.87 earnings per share. As a group, equities analysts anticipate that Danaher Co. will post 7.63 EPS for the current year.

Danaher Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Investors of record on Thursday, March 28th will be paid a $0.27 dividend. This is an increase from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 dividend on an annualized basis and a yield of 0.43%. The ex-dividend date of this dividend is Wednesday, March 27th. Danaher’s dividend payout ratio is presently 15.02%.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on DHR shares. JPMorgan Chase & Co. lifted their price target on shares of Danaher from $250.00 to $270.00 and gave the stock an “overweight” rating in a report on Wednesday, December 20th. Wolfe Research began coverage on shares of Danaher in a report on Wednesday, December 13th. They set a “peer perform” rating on the stock. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. TheStreet raised shares of Danaher from a “c+” rating to a “b-” rating in a report on Friday, December 8th. Finally, Raymond James boosted their target price on shares of Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. Seven research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $266.00.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.